Monitoring of Molecular Responses to Tirabrutinib in a Cohort of Exceptional Responders with Relapsed/refractory Mantle Cell Lymphoma

Overview

Journal EJHaem

Specialty Hematology

Date 2024 Aug 19

PMID 39157626

Authors

Abdullah N M Alqahtani

Sandrine Jayne

Matthew J AHearne

Christopher S Trethewey

Sai S Duraisingham

Susann Lehmann

Caroline M Cowley

Martin J S Dyer

Harriet S Walter

Affiliations

Soon will be listed here.

References

Dreyling M, Goy A, Hess G, Kahl B, Hernandez-Rivas J, Schuier N . Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up. Hemasphere. 2022; 6(5):e712. PMC: 9010121. DOI: 10.1097/HS9.0000000000000712. View

Strati P, de Vos S, Ruan J, Maddocks K, Flowers C, Rule S . Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study. Haematologica. 2021; 106(10):2774-2778. PMC: 8485664. DOI: 10.3324/haematol.2021.278654. View

Wang M, Rule S, Zinzani P, Goy A, Casasnovas O, Smith S . Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2017; 391(10121):659-667. PMC: 7864374. DOI: 10.1016/S0140-6736(17)33108-2. View

Burger J . Bruton Tyrosine Kinase Inhibitors: Present and Future. Cancer J. 2019; 25(6):386-393. PMC: 7083517. DOI: 10.1097/PPO.0000000000000412. View

Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H . Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022; 139(21):3148-3158. PMC: 9136878. DOI: 10.1182/blood.2021014162. View

Wilson W, Young R, Schmitz R, Yang Y, Pittaluga S, Wright G . Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015; 21(8):922-6. PMC: 8372245. DOI: 10.1038/nm.3884. View

Wang M, Rule S, Zinzani P, Goy A, Casasnovas O, Smith S . Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019; 33(11):2762-2766. DOI: 10.1038/s41375-019-0575-9. View

Wheeler D, Takebe N, Hinoue T, Hoadley K, Cardenas M, Hamilton A . Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell. 2020; 39(1):38-53.e7. PMC: 8478080. DOI: 10.1016/j.ccell.2020.10.015. View

Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H . Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol. 2020; 23(1):122-133. PMC: 7850159. DOI: 10.1093/neuonc/noaa145. View

10.

Rule S, Cartron G, Fegan C, Morschhauser F, Han L, Mitra S . Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). Leukemia. 2019; 34(5):1458-1461. PMC: 7192842. DOI: 10.1038/s41375-019-0658-7. View

11.

Cooper A, Tumuluru S, Kissick K, Venkataraman G, Song J, Lytle A . CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition. J Clin Oncol. 2023; 42(4):467-480. DOI: 10.1200/JCO.23.01574. View

12.

Young R, Wu T, Schmitz R, Dawood M, Xiao W, Phelan J . Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proc Natl Acad Sci U S A. 2015; 112(44):13447-54. PMC: 4640740. DOI: 10.1073/pnas.1514944112. View

13.

Wilson W, Wright G, Huang D, Hodkinson B, Balasubramanian S, Fan Y . Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021; 39(12):1643-1653.e3. PMC: 8722194. DOI: 10.1016/j.ccell.2021.10.006. View

14.

Martin P, Maddocks K, Leonard J, Ruan J, Goy A, Wagner-Johnston N . Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016; 127(12):1559-63. DOI: 10.1182/blood-2015-10-673145. View